Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
Hs 578T	CAL-101	1		sigmoid	sigmoid	Hs578T idelalisib 1	8	2.050	27.9	0.72	0.0764	4.56	0.356	0.688	0.945	0.000168	NA	18.7	0.734	0.925	18.7	0.0	0.568	0.941	0.000203	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
HCC38	Pictilisib	3	72	sigmoid	sigmoid	HCC38 pictilisib 0 3 72	8	1.420	3.12	0.499	0.129	2.45	0.0818	0.738	0.976	1.33e-05	NA	20.5	0.664	0.911	2.24	0.401	0.731	0.974	1.7e-05	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
Hs 578T	Everolimus	2		sigmoid	sigmoid	Hs578T everolimus 2	8	2.550	3210000000.0	0.626	0.335	0.000205	0.476	0.1	0.791	0.00913	NA	18938.0	0.59	0.627	0.000153	0.422	0.1	0.745	0.0166	NA
HCC70	PIK-93	1	72	sigmoid	sigmoid	HCC70 PIK-93 0 1 72	8	1.442	3.47	0.482	0.137	18.6	-1.0	0.656	0.774	0.0116	NA	10.7	0.649	0.904	10.7	0.0	0.632	0.746	0.0163	NA
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
HCC38	TGX221	3	72	sigmoid	sigmoid	HCC38 TGX-221 0 3 72	8	1.484	3688.0	0.815	0.0743	320.0	0.243	0.273	0.867	0.00233	NA	3261706.0	0.866	0.945	320.0	0.458	0.269	0.867	0.00238	NA
HCC70	Torin1	3	72	sigmoid	sigmoid	HCC70 Torin1 0 3 72	8	2.415	3.74	0.495	0.279	0.0352	0.496	1.02	0.994	2.6e-07	NA	5.73	0.495	0.709	0.0284	0.498	1.06	0.994	2.26e-07	NA
HCC70	Sirolimus	1	72	sigmoid	sigmoid	HCC70 rapamycin 0 1 72	8	1.416	37.6	0.533	0.397	0.00426	0.298	0.1	0.742	0.0172	NA	125000000.0	0.687	0.732	0.00186	0.541	0.1	0.74	0.0175	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-549	CAL-101	3	72	sigmoid	sigmoid	BT549 idelalisib 0 3 72	8	1.770	43.0	0.79	0.0687	320.0	-0.664	0.421	0.862	0.00261	NA	118.0	0.822	0.941	118.0	0.0	0.425	0.854	0.00309	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
HCC70	Alpelisib	1	72	sigmoid	sigmoid	HCC70 alpelisib 0 1 72	8	1.383	4.4	0.574	0.105	20.4	-1.0	0.717	0.78	0.0106	NA	11.9	0.718	0.929	11.9	0.0	0.732	0.768	0.0124	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-20	AS605240	2	72	sigmoid	sigmoid	BT20 AS-605240 0 2 72	8	1.846	4509270.0	0.729	0.203	320.0	0.31	0.101	0.845	0.00373	NA	4.4e+12	0.764	0.821	56.5	0.46	0.101	0.843	0.00388	NA
HCC1806	MK2206	1	72	sigmoid	sigmoid	HCC1806 MK-2206 0 1 72	8	2.746	47.7	0.818	0.0504	320.0	-0.715	0.466	0.981	7.02e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC38	PIK-93	3	72	sigmoid	sigmoid	HCC38 PIK-93 0 3 72	8	1.382	5.05	0.598	0.061	2.34	0.358	1.63	0.919	0.000533	NA	Inf	0.734	0.959	2.23	0.586	1.64	0.914	0.000645	NA
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
HCC70	Everolimus	3	72	sigmoid	sigmoid	HCC70 everolimus 0 3 72	8	2.401	530906.0	0.749	0.195	0.072	0.603	0.1	0.706	0.0255	NA	381983.0	0.725	0.782	0.0137	0.59	0.1	0.706	0.0255	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-549	Everolimus	1	72	sigmoid	sigmoid	BT549 everolimus 0 1 72	8	1.772	5.64	0.503	0.444	1e-05	0.367	0.1	0.911	0.000706	NA	437200.0	0.603	0.641	0.000146	0.444	0.1	0.858	0.00286	NA
Hs 578T	CAL-101	2		sigmoid	sigmoid	Hs578T idelalisib 2	8	2.534	57.5	0.801	0.0636	320.0	-0.507	0.408	0.979	9.58e-06	NA	Inf	0.766	0.923	4.27	0.505	0.495	0.975	1.65e-05	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)